Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.50 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | PDE4A | P27815 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.48 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.48 |
| ▸ | AHR | P35869 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20162273 | 0.94 | MEN1 (0.51) | NR1H4ABCG2CYP1A2 | |
| SCHEMBL6380238 | 0.88 | NR1H4 (0.47) | NR1H4HDAC10HDAC6 | |
| SCHEMBL20162270 | 0.87 | NR1H4 (0.56) | NR1H4CYP1A2 | |
| SCHEMBL6484837 | 0.86 | NR1H4 (0.46) | NR1H4CYP1A2 | |
| SCHEMBL31483445 | 0.86 | NR1H4 (0.56) | NR1H4ABCG2KDM4ECYP1A2TP53 | |
| SCHEMBL11330304 | 0.86 | NR1H4 (0.67) | NR1H4ABCG2KDM4ECYP1A2SMN1; SMN2 | |
| SCHEMBL31483447 | 0.85 | TLR4 (0.54) | NR1H4TSHR | |
| SCHEMBL12869940 | 0.85 | NR1H4 (0.50) | NR1H4CYP1A2 | |
| SCHEMBL19994224 | 0.84 | TP53 (0.53) | NR1H4ABCG2TP53TSHR | |
| SCHEMBL141697 | 0.84 | KDM4E (0.53) | ABCG2KDM4ETP53TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 198 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12617955-B2 | Additive production process with a thermoplastic radically cross-linkable construction material | STRATASYS, INC. (US) | 2026-05-05 | — | — | US | disclosed |
| US-12594700-B2 | Coatings from polyisocyanurate coatings (rim) and their use in injection molding processes | COVESTRO DEUTSCHLAND AG (DE) | 2026-04-07 | — | — | US | disclosed |
| US-12447699-B2 | Anisotropic composite materials based on polyisocyanates | COVESTRO DEUTSCHLAND AG (DE) | 2025-10-21 | — | — | US | disclosed |
| US-12331214-B2 | Resistant 2K-PUR coatings | COVESTRO INTELLECTUAL PROPERTY GMBH & CO. KG (DE) | 2025-06-17 | — | — | US | disclosed |
| EP-3953407-B1 | 2-COMPONENT POLYURETHANE COATINGS WITH IMPROVED POT LIFE WITHOUT LOST WEATHERING STABILITY | COVESTRO DEUTSCHLAND AG (DE) | 2025-04-30 | — | — | EP | disclosed |
| EP-3994192-B1 | RESISTANT 2K-PUR COATINGS | COVESTRO DEUTSCHLAND AG (DE) | 2025-04-30 | — | — | EP | disclosed |
| CN-119841980-A | Catalyst for olefin polymerization and olefin polymerization method | 中国石油化工股份有限公司 | 2025-04-18 | — | — | CN | disclosed |
| CN-119841979-A | Catalyst for olefin polymerization and olefin polymerization method | 中国石油化工股份有限公司 | 2025-04-18 | — | — | CN | disclosed |
| EP-4058499-B1 | POLYSILOXANE FUNCTIONALIZED POLYURETHANES FOR ENHANCING HYDROPHOBISATION OF SURFACES | COVESTRO DEUTSCHLAND AG (DE) | 2024-12-04 | — | — | EP | disclosed |
| EP-3554787-B1 | METHOD FOR PRODUCING A 3D PRINTED FOAM-FILLED OBJECT | STRATASYS INC (US) | 2024-09-25 | — | — | EP | disclosed |
| EP-0021004-B1 | SELFHARDENABLE MATERIAL FOR THE MANUFACTURE OF A WEATHER RESISTANT, NON YELLOWING ORTHOPEDIC BANDAGE | BAYER AG (DE) | 1982-08-04 | — | — | EP | disclosed |
| EP-0007502-B1 | PROCESS FOR PREPARING FOAMED MOULDED MATERIALS | BAYER AG (DE) | 1981-12-30 | — | — | EP | disclosed |
| EP-0021004-A1 | Selfhardenable material for the manufacture of a weather resistant, non yellowing orthopedic bandage | BAYER AG (DE) | 1981-01-07 | — | — | EP | disclosed |
| US-4189542-A | Process for the production of foam moldings having an impervious outer skin using semi-prepolymer prepared from isocyanates such as isophorone diisocyanate | BAYER AKTIENGESELLSCHAFT (DE) | 1980-02-19 | — | — | US | disclosed |
| EP-0007502-A1 | Process for preparing foamed moulded materials | BAYER AG (DE) | 1980-02-06 | — | — | EP | disclosed |
| EP-0001965-A1 | Process for the preparation of foamed materials | BAYER AG (DE) | 1979-05-30 | — | — | EP | disclosed |
| US-4123418-A | BIS-(U8I8I8L8L-PENTAMETHY TETRAMETHYL-4-PIPERIDYL)-SUBERATE | CIBA-GEIGY CORPORATION (US) | 1978-10-31 | — | — | US | disclosed |
| US-4110304-A | STERICALLY HINDERED CYCLIC AMINE | CIBA-GEIGY CORPORATION (US) | 1978-08-29 | — | — | US | disclosed |
| US-4061631-A | STABILIZER | CIBA-GEIGY CORPORATION (US) | 1977-12-06 | — | — | US | disclosed |
| US-3943098-A | 1-Aza-4-thiacyclohexane-4,4-dioxide derivatives and their use as agents protecting against light rays | CIBA-GEIGY CORPORATION (US) | 1976-03-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12617955-B2 | Additive production process with a thermoplastic radically cross-linkable construction material | UBE2G2, MTCL3, RAD51 | NR1H4 4772/4885ABCG2 3837/4885KDM4E 1961/4885 |
| US-12594700-B2 | Coatings from polyisocyanurate coatings (rim) and their use in injection molding processes | TST, C9, ESD | NR1H4 4624/4885ABCG2 4605/4885KDM4E 783/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.